La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cerro De Pasco Resources a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cerro De Pasco Resources..

Cerro De Pasco Resources (OTC:GPPRF) Azioni, Catena delle Opzioni

Cerro De Pasco Resources Inc is a natural resource company engaged in acquiring and exploring mineral properties. It treats and reprocesses all dumps, tailings, mining waste, and material resources in the Cerro de Pasco Region in Peru. Its projects include the Quiulacocha tailings and Excelsior Stockpile. It also produces zinc and lead-silver concentrates from the Santander mine in Peru.

CERRO DE PASCO RES INC by Cerro De Pasco Res Inc.

Cerro De Pasco Resources Inc

News

Guidance

Six Flags Entertainment Says It Is Targeting At Least $800M Of Annual Unlevered Pre-tax Free Cash Flow By 2027

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and maintains $84 price target.

Price Target

Reiteration

Analyst Ratings

CRSP

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $84 Price Target

<a href="https://www.bloomberg.com/news/articles/2024-11-06/kkr-is-said-to-consider-selling-750-million-stake-in-jb-pharma?sref=y3YMCJ4e" title="https://www.bloomberg.com/news/articles/2024-11-06/kkr-is-said-to-consider-selling-750-million-stake-in-jb-pharma?sref=y3YMCJ4e">https://www.bloomberg.com/news/articles/2024-11-06/kkr-is-said-to-consider-selling-750-million-stake-in-jb-pharma?sref=y3YMCJ4e</a>

Asset Sales

Bloomberg Reported KKR Said To Consider Selling $750M Stake In JB Pharma

Toyota Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) reported quarterly sales of $76.29 billion which beat the analyst consensus estimate of $72.27 billion by 5.57 percent.&nbsp;

Earnings

Earnings Beats

Toyota Motor Q2 Sales $76.29B Beat $72.27B Estimate

Cedar Fair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) reported quarterly earnings of $1.10 per share. The company reported quarterly sales of $1.348 billion which beat the analyst consensus estimate of $1.339 billion by 0.67 percent. This is a 60.09 percent increase over sales of $842.009 million the same period last year.

Earnings Misses

Cedar Fair Q3 2024 Adj. EPS $1.10, Sales $1.348B Beat $1.339B Estimate

Morgan Stanley analyst Joseph Moore maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Equal-Weight and lowers the price target from $250 to $235.

NXPI

Morgan Stanley Maintains Equal-Weight on NXP Semiconductors, Lowers Price Target to $235

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) with a Buy and maintains $11 price target.

TCRX

Needham Reiterates Buy on TScan Therapeutics, Maintains $11 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) with a Buy and maintains $32 price target.

IOVA

HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy and raises the price target from $80 to $95.

ACLX

HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $95

Deutsche Bank analyst David Begleiter upgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowers the price target from $135 to $110.

Upgrades

Deutsche Bank Upgrades Celanese to Buy, Lowers Price Target to $110

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

KPTI

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

Needham analyst Mike Matson reiterates NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and maintains $19 price target.

Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target

Needham analyst Gil Blum reiterates Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy and maintains $96 price target.

Needham Reiterates Buy on Arcellx, Maintains $96 Price Target

Deutsche Bank analyst Nicole Deblase maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and raises the price target from $136 to $140.

Deutsche Bank Maintains Buy on Emerson Electric, Raises Price Target to $140

KRKR

36kr Holdings Inc. Announced That It Has Recently Teamed Up With Soften Corporation To Launch An Innovative News Hub, The "36kr Market Watch" Wechat Mini Program

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Arcus Biosciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) with a Neutral and maintains $20 price target.

RCUS

HC Wainwright & Co. Reiterates Neutral on Arcus Biosciences, Maintains $20 Price Target

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are up by over 13% in pre-market trading on Wednesday over a likely Donald Trump victory in the <a href="https://www.benzinga.com/topic/2024-election" target="_blank" rel="noreferrer noopener">U.S. Presidential elections</a>.
What Happened: According <a href="https://www.nytimes.com/live/2024/11/05/us/trump-harris-election" target="_blank" rel="noreferrer noopener">to</a> The New York Times, Trump currently has over 95% chance of victory given he already has <a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f" target="_blank" rel="noreferrer noopener">267 of the 270 electoral votes needed to win</a>.
At the time of writing, the Tesla stock was up 13.3% in premarket trading, at $284.90, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Tesla CEO&nbsp;Elon Musk&nbsp;endorsed Trump in July and has been actively campaigning for the former President&nbsp;<a href="https://www.benzinga.com/news/24/11/41709658/stephen-king-slams-elon-musk-claims-most-of-his-posts-spread-pro-trump-disinformation-and-outright-l" target="_blank" rel="noreferrer noopener">both offline and online</a>. Musk even campaigned for Trump in the swing state of Pennsylvania in October.
Trump, meanwhile, has expressed his intent to set up a&nbsp;<a href="https://www.benzinga.com/government/24/09/40739165/trump-plans-to-appoint-elon-musk-to-government-efficiency-commission-if-elected-tesla-ceo-says-hell" target="_blank" rel="noreferrer noopener">government efficiency commission</a>&nbsp;led by Musk if elected President. The commission will be tasked with conducting a complete financial and performance audit of the federal government and recommending reforms, Trump said in September.
According to&nbsp;Wedbush&nbsp;analyst&nbsp;Dan Ives, the&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41766869/trump-win-biggest-positive-for-elon-musks-tesla-tech-bull-says-it-could-boost-ev-gi" target="_blank" rel="noreferrer noopener">biggest positive from a Trump win would be for Tesla and Musk</a>.
"We believe a Trump win is a negative for the EV industry as the EV rebates/tax incentives get pulled, however for Tesla a huge positive for scale/price advantage," Ives said on Wednesday. The analyst added that a Trump win could add $40-$50 to Tesla's stock.
Tesla&#8217;s Frankfurt-listed shares are also up by over 14.5%.
Price Action: Year-to-date, Tesla shares are up 1.2%, after the stock closed up 3.5% at $251.44 on Tuesday, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41738613/elon-musk-rejects-rumors-of-a-tesla-phone-but-says-the-ev-giant-will-have-to-make-one-if-this-happen" target="_blank" rel="noreferrer noopener">Elon Musk Rejects Rumors Of A Tesla Phone, But Says The EV Giant Will Have To Make One If This Happens</a></li>
</ul>
Photo courtesy: Tesla

Equities

WIIM

Pre-Market Outlook

Markets

Tech

TSLA

Tesla Stock Surges Over 13% In Premarket: What Is Going On

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $85 to $60.

APLS

Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60

Needham analyst Mayank Tandon maintains Payoneer Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) with a Buy and raises the price target from $10 to $14.

PAYO

Needham Maintains Buy on Payoneer Global, Raises Price Target to $14

HC Wainwright &amp; Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) with a Buy and maintains $11 price target.

Comments

Cerro De Pasco Resources

Cerro De Pasco Resources (GPPRF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO